EX-16.2 2 ex16-2.htm EXHIBIT 16.2 ex1.htm

Exhibit 16.2

  

 

March 25, 2016

 


Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549-7561

 

Dear Sirs/Madams:

 

We have read Item 4.01 of Diffusion Pharmaceuticals Inc.’s Form 8-K/A dated March 25, 2016, and have the following comments:

 

 

1.

We agree with the statements made in paragraphs one through four.

 

2.

We have no basis to agree or disagree with the statements made in paragraphs five and six.

 

 

Yours truly,

 

/s/ Deloitte & Touche LLP